Literature DB >> 26040648

Change in volume parameters induced by neoadjuvant chemotherapy provide accurate prediction of overall survival after resection in patients with oesophageal cancer.

Dietmar Tamandl1, Richard M Gore2, Barbara Fueger3, Patrick Kinsperger3, Michael Hejna4, Matthias Paireder5, Alexander Haug3, Sebastian F Schoppmann5, Ahmed Ba-Ssalamah3.   

Abstract

OBJECTIVES: To assess the prognostic value of volumetric parameters measured with CT and PET/CT in patients with neoadjuvant chemotherapy (NACT) and resection for oesophageal cancer (EC).
METHODS: Patients with locally advanced EC, who were treated with NACT and resection, were retrospectively analysed. Data from CT volumetry and (18) F-FDG PET/CT (maximum standardized uptake [SUVmax], metabolic tumour volume [MTV], and total lesion glycolysis [TLG]) were recorded before and after NACT. The impact of volumetric parameter changes induced by NACT (MTVRATIO, TLGRATIO, etc.) on overall survival (OS) was assessed using a Cox proportional hazards model.
RESULTS: Eighty-four patients were assessed using CT volumetry; of those, 50 also had PET/CT before and after NACT. Low post-treatment CT volume and thickness, MTV, TLG, and SUVmax were all associated with longer OS (p < 0.05), as were CTthicknessRATIO, MTVRATIO, TLGRATIO, and SUVmaxRATIO (p < 0.05). In the multivariate analysis, only MTVRATIO (Hazard ratio, HR 2.52 [95% Confidence interval, CI 1.33-4.78], p = 0.005), TLGRATIO (HR 3.89 [95%CI 1.46-10.34], p = 0.006), and surgical margin status (p < 0.05), were independent predictors of OS.
CONCLUSIONS: MTVRATIO and TLGRATIO are independent prognostic factors for survival in patients after NACT and resection for EC. KEY POINTS: • Change in PET parameters shows close correlation to survival in oesophageal cancer. • Association with OS is independent of changes in SUVmax and CT volume. • Metabolic parameters after NACT correlate with pathologic response and nodal status. • Metabolic parameters may be better suited than SUVmax for response assessment.

Entities:  

Keywords:  Metabolic tumour volume; Neoadjuvant chemotherapy; Oesophageal cancer; Overall survival; Response assessment

Mesh:

Substances:

Year:  2015        PMID: 26040648     DOI: 10.1007/s00330-015-3860-7

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  36 in total

1.  Tumor volume of resectable adenocarcinoma of the esophagogastric junction at multidetector CT: association with regional lymph node metastasis and N stage.

Authors:  Rui Li; Tian-wu Chen; Jiani Hu; Dan-dan Guo; Xiao-ming Zhang; Dan Deng; Hang Li; Xiao-li Chen; Hong-jie Tang
Journal:  Radiology       Date:  2013-05-08       Impact factor: 11.105

2.  Pre-treatment metabolic tumor volume and total lesion glycolysis are useful prognostic factors for esophageal squamous cell cancer patients.

Authors:  Yi-Min Li; Qin Lin; Long Zhao; Li-Chen Wang; Long Sun; Ming-Ming Dai; Zuo-Ming Luo; Hua Zheng; Hua Wu
Journal:  Asian Pac J Cancer Prev       Date:  2014

3.  Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status.

Authors:  Min P Kim; Arlene M Correa; Jared Lee; David C Rice; Jack A Roth; Reza J Mehran; Garrett L Walsh; Jaffer A Ajani; Dipen M Maru; Joe Y Chang; Edith M Marom; Homer A Macapinlac; Jeff H Lee; Ara A Vaporciyan; Thomas Rice; Stephen G Swisher; Wayne L Hofstetter
Journal:  Ann Thorac Surg       Date:  2010-09       Impact factor: 4.330

4.  Accuracy of hydro-multidetector row CT in the local T staging of oesophageal cancer compared to postoperative histopathological results.

Authors:  Ahmed Ba-Ssalamah; Wolfgang Matzek; Susanne Baroud; Nina Bastati; Johannes Zacherl; Sebastian F Schoppmann; Michael Hejna; Fritz Wrba; Michael Weber; Christian J Herold; Richard M Gore
Journal:  Eur Radiol       Date:  2011-06-28       Impact factor: 5.315

5.  Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer.

Authors:  Wouter van Elmpt; Michel Ollers; Anne-Marie C Dingemans; Philippe Lambin; Dirk De Ruysscher
Journal:  J Nucl Med       Date:  2012-08-09       Impact factor: 10.057

6.  Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus.

Authors:  B D Minsky; D Neuberg; D P Kelsen; T M Pisansky; R J Ginsberg; T Pajak; M Salter; A B Benson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-02-01       Impact factor: 7.038

7.  Temporal trends in long-term survival and cure rates in esophageal cancer: a SEER database analysis.

Authors:  Attila Dubecz; Isabell Gall; Norbert Solymosi; Michael Schweigert; Jeffrey H Peters; Marcus Feith; Hubert J Stein
Journal:  J Thorac Oncol       Date:  2012-02       Impact factor: 15.609

8.  Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy.

Authors:  Ambros J Beer; Hinrich A Wieder; Florian Lordick; Katja Ott; Michael Fischer; Karen Becker; Jens Stollfuss; Ernst J Rummeny
Journal:  Radiology       Date:  2006-03-16       Impact factor: 11.105

9.  Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma.

Authors:  Seung Hyup Hyun; Joon Young Choi; Young Mog Shim; Kwhanmien Kim; Su Jin Lee; Young Seok Cho; Ji Young Lee; Kyung-Han Lee; Byung-Tae Kim
Journal:  Ann Surg Oncol       Date:  2009-10-14       Impact factor: 5.344

10.  Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer.

Authors:  Connie Yip; Vicky Goh; Andrew Davies; James Gossage; Rosalind Mitchell-Hay; Orla Hynes; Nick Maisey; Paul Ross; Andrew Gaya; David B Landau; Gary J Cook; Nyree Griffin; Robert Mason
Journal:  Eur Radiol       Date:  2014-02-18       Impact factor: 5.315

View more
  11 in total

1.  Oesophageal cancer staging: a minefield of measurements-author's reply.

Authors:  Francesco Giganti; Alessandro Ambrosi; Antonio Esposito; Alessandro Del Maschio; Francesco De Cobelli
Journal:  Br J Radiol       Date:  2017-01-30       Impact factor: 3.039

Review 2.  Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma.

Authors:  Kazuto Harada; Dilsa Mizrak Kaya; Anthony Lopez; Hideo Baba; Jaffer A Ajani
Journal:  Ann Transl Med       Date:  2018-02

3.  PET Imaging and Rate of Pathologic Complete Response in Esophageal Squamous Cell Carcinoma.

Authors:  M Hart Squires; Nicole Gower; Jennifer H Benbow; Erin E Donahue; Casey E Bohl; Roshan S Prabhu; Joshua S Hill; Jonathan C Salo
Journal:  Ann Surg Oncol       Date:  2021-10-09       Impact factor: 5.344

4.  Restaging oesophageal cancer after neoadjuvant therapy with (18)F-FDG PET-CT: identifying interval metastases and predicting incurable disease at surgery.

Authors:  John M Findlay; Richard S Gillies; James M Franklin; Eugene J Teoh; Greg E Jones; Sara di Carlo; Fergus V Gleeson; Nicholas D Maynard; Kevin M Bradley; Mark R Middleton
Journal:  Eur Radiol       Date:  2016-02-16       Impact factor: 5.315

5.  Opportunistic body composition evaluation in patients with esophageal adenocarcinoma: association of survival with 18F-FDG PET/CT muscle metrics.

Authors:  Cathy Zhou; Brent Foster; Rosalie Hagge; Cameron Foster; Leon Lenchik; Abhijit J Chaudhari; Robert D Boutin
Journal:  Ann Nucl Med       Date:  2019-12-10       Impact factor: 2.668

6.  Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer.

Authors:  Miso Kim; Bhumsuk Keam; Tae-Min Kim; Hoon-Gu Kim; Jin-Soo Kim; Sung Sook Lee; Seong Hoon Shin; Min Kyoung Kim; Keon Uk Park; Dong-Wan Kim; Hwan Jung Yun; Jong Seok Lee; Dae Seog Heo
Journal:  Cancer Res Treat       Date:  2016-07-28       Impact factor: 4.679

7.  The impact of intratumoral metabolic heterogeneity on postoperative recurrence and survival in resectable esophageal squamous cell carcinoma.

Authors:  Xinzhe Dong; Xiaorong Sun; Xianguang Zhao; Wanqi Zhu; Lu Sun; Yong Huang; Wenwu Li; Honglin Wan; Ligang Xing; Jinming Yu
Journal:  Oncotarget       Date:  2017-02-28

8.  The Correlation Between Computed Tomography Volumetry and Prognosis of Advanced Gastric Cancer Treated with Neoadjuvant Chemotherapy.

Authors:  Chao Chen; Hao Dong; Chunhui Shou; Xiaoxiao Shi; Qing Zhang; Xiaosun Liu; Kankai Zhu; Baishu Zhong; Jiren Yu
Journal:  Cancer Manag Res       Date:  2020-02-03       Impact factor: 3.989

9.  Prognostic value of SUR in patients with trimodality treatment of locally advanced esophageal carcinoma.

Authors:  Rebecca Bütof; Frank Hofheinz; Klaus Zöphel; Julia Schmollack; Christina Jentsch; Sebastian Zschaeck; Jörg Kotzerke; Jörg van den Hoff; Michael Baumann
Journal:  J Nucl Med       Date:  2018-08-30       Impact factor: 10.057

10.  Usefulness of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography for predicting the prognosis and treatment response of neoadjuvant therapy for pancreatic ductal adenocarcinoma.

Authors:  Takahiro Yokose; Minoru Kitago; Yohji Matsusaka; Yohei Masugi; Masahiro Shinoda; Hiroshi Yagi; Yuta Abe; Go Oshima; Shutaro Hori; Yutaka Endo; Kenji Toyama; Yu Iwabuchi; Ryo Takemura; Ryota Ishii; Tadaki Nakahara; Shigeo Okuda; Masahiro Jinzaki; Yuko Kitagawa
Journal:  Cancer Med       Date:  2020-04-12       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.